BackgroundCheck.run
Search For

Dwight D Hanshew, 581328 Cherry St, Morgantown, WV 26505

Known as:
Dwight Douglas Hanshew Dwight D Hanshaw Kurtis Wilcox
Related to:
Sherri L Hanshew 50

Dwight Hanshew Phones & Addresses

1328 Cherry St, Morgantown, WV 26505    304-5997826   

1265 Kings Rd, Morgantown, WV 26508    304-2922492   

Canonsburg, PA   

78 Schreiner Dr, North Wales, PA 19454    215-9971401   

Washington, PA   

Montgomery, PA   

Work

Company: Lachman consultants 2012 Position: Senior associate, compliance practice

Education

School / High School: University of Pittsburgh, Katz Business School - Center for Executive Education- Pittsburgh, PA 2000 Specialities: MBA Essentials
Get Report
Control this profile

Mentions for Dwight D Hanshew

Dwight Hanshew resumes & CV records

Resumes

Dwight Hanshew Photo 10

Dwight Hanshew - North Wales, PA

Work:
Lachman Consultants 2012 to Present
Senior Associate, Compliance Practice DDH Pharma Consulting, LLC 2012 to Present
Principal URL PHARMA, INC - Philadelphia, PA 2009 to 2012
Sr. Vice President of Pharmaceutical Operations URL PHARMA, INC - Philadelphia, PA 2007 to 2009
Sr. Vice President of Operations URL PHARMA, INC - Philadelphia, PA 2004 to 2007
Vice President of Quality Operations MYLAN PHARMACEUTICALS - Morgantown, WV 2003 to 2004
Director of Quality Control MYLAN PHARMACEUTICALS - Morgantown, WV 1998 to 2003
Associate Director Analytical R&D MYLAN PHARMACEUTICALS - Morgantown, WV 1990 to 1998
Manager of Quality Control
Education:
University of Pittsburgh, Katz Business School - Center for Executive Education - Pittsburgh, PA 2000
MBA Essentials West Virginia University 1991
MS in Chemistry Centre College of Kentucky 1988
BS in Chemistry

Publications & IP owners

Us Patents

Storage Stable Thyroxine Active Drug Formulations And Methods For Their Production

US Patent:
2004001, Jan 22, 2004
Filed:
May 20, 2003
Appl. No.:
10/441259
Inventors:
Dwight Hanshew - Morgantown WV, US
David Wargo - Pittsburgh PA, US
International Classification:
A61K031/198
A61K009/20
US Classification:
424/465000, 514/567000
Abstract:
This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance and an antioxidant, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, butylated hydroxyanisole is the preferred antioxidant. Additional preferred excipients include, for example, microcrystalline cellulose, sucrose, mannitol, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Storage Stable Thyroxine Active Drug Formulations And Methods For Their Production

US Patent:
2004003, Feb 19, 2004
Filed:
May 22, 2003
Appl. No.:
10/443135
Inventors:
Dwight Hanshew - Morgantown WV, US
David Wargo - Pittsburgh PA, US
International Classification:
A61K031/70
A61K009/20
A61K031/198
US Classification:
424/465000, 514/567000, 514/023000
Abstract:
This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Storage Stable Thyroxine Active Drug Formulations And Methods For Their Production

US Patent:
2005023, Oct 20, 2005
Filed:
Jun 3, 2005
Appl. No.:
11/143645
Inventors:
Dwight Hanshew - North Wales PA, US
David Wargo - Pittsburgh PA, US
International Classification:
A61K009/20
A61K031/198
US Classification:
424464000, 514567000
Abstract:
This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the9 preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Storage Stable Thyroxine Active Drug Formulations And Methods For Their Production

US Patent:
2003009, May 29, 2003
Filed:
Nov 13, 2001
Appl. No.:
09/987130
Inventors:
Dwight Hanshew - Morgantown WV, US
David Wargo - Pittsburgh PA, US
International Classification:
A61K031/198
A61K009/20
US Classification:
424/465000, 514/567000
Abstract:
This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Storage Stable Thyroxine Active Drug Formulations And Methods For Their Production

US Patent:
2003009, May 29, 2003
Filed:
Nov 13, 2001
Appl. No.:
09/987160
Inventors:
Dwight Hanshew - Morgantown WV, US
David Wargo - Pittsburgh PA, US
International Classification:
A61K031/198
A61K009/20
US Classification:
424/465000, 514/567000
Abstract:
This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance and an antioxidant, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, butylated lydroxyanisole is the preferred antioxidant. Additional preferred excipients include, for example, microcrystalline cellulose, sucrose, mannitol, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Possible Relatives

David M Hanshew  Donald E Hanshew  Donna J Hanshew  Elizabeth A Hanshew  James A Hanshew  Jason Z Hanshew  Jeffrey S Hanshew  Dwight Johnson  Dwight R Standridge  Dwight C Stanford 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.